Тромбоэмболические осложнения у пациентов с воспалительными заболеваниями кишечника


DOI: https://dx.doi.org/10.18565/pharmateca.2019.2.10-19

А.А. Лищинская, А.В. Каграманова, М.Ю. Звяглова, О.В. Князев, Н.А. Фадеева, Д.С. Кулаков, А.И. Парфенов

Московский клинический научно-практический центр им. А.С. Логинова ДЗ Москвы, Москва, Россия
В обзоре представлены современные сведения о тромбоэмболических осложнениях (ТЭО), являющихся одним из характерных проявлений воспалительных заболеваний кишечника (ВЗК). Этиопатогенетическая связь между ВЗК и развитием ТЭО пока недостаточно изучена, но можно предположить, что помимо приобретенных факторов гиперкоагуляции существуют и наследственные факторы, способствующие развитию ТЭО. Гиперкоагуляция, как полагают многие исследователи, участвует в патогенезе ВЗК, и будущее изучение этого феномена поможет выявить потенциальные терапевтические мишени для лечения ВЗК. ТЭО ухудшают прогноз заболевания и повышают летальность от ВЗК. Необходимо повышать осведомленность врачей о рисках развития ТЭО, мерах первичной и вторичной профилактики, о способах их лечения, что имеет важное практическое значение в терапии ВЗК. В перспективе следует уточнить спорные проблемы тромбопрофилактики амбулаторных пациентов с активным заболеванием, тромбопрофилактики пациентов в период после выписки из стационара, а также решить проблему продолжительности тромбопрофилактики. В настоящее время существует необходимость предоставления клиницистам надежных методов или маркеров оценки протромботического риска для пациентов с ВЗК с целью оперативного применения профилактических мер.
Ключевые слова: воспалительные заболевания кишечника, болезнь Крона, язвенный колит, тромбоэмболические осложнения

Литература


1. Fumery M., Xiaocang C., Dauchet L., et al. Thromboembolic events and cardiovascular mortality in inflammatory bowel diseases: a meta-analysis of observational studies. J Crohns Colitis. 2014;8:469–79. Doi: 10.1016/j.crohns.2013.09.021.

2. Yoshida H., Granger D.N. Inflammatory bowel disease: a paradigm for the link between coagulation and inflammation. Inflamm. Bowel Dis. 2009;15:1245–55.

3. Bargen J.A., Barker N.W. Extensive arterial and venous thrombosis complicating chronic ulcerative colitis. Arch Intern Med. 1936;58:17–31. Doi: 10.1001/archinte.1936.00170110025002.

4. Talbot R.W., Heppell J., Dozois R.R., Beart R.W. Vascular complications of inflammatory bowel disease. Mayo Clin Proc. 1986;61:140–45. Doi: 10.1016/S0025-6196(12)65200-8.

5. Edwards F.C., Truelove S.C. The course and prognosis of ulcerative colitis. III. Complications. Gut. 1964;5:1–22. Doi: 10.1136/gut.5.1.1.

6. Koenigs K.P., McPhedran P., Spiro H.M. Thrombosis in inflammatory bowel disease. J Clin Gastroenterol. 1987;9:627–31. Doi: 10.1097/00004836-198712000-00004.

7. Sloan W.P., Bargen J.A., Gage R.P. Life histories of patients with chronic ulcerative colitis: a review of 2,000 cases. Gastroenterology. 1950;16:25–38.

8. Ricketts W.E., Palmer W.L. Complications of chronic non-specifi ulcerative colitis. Gastroenterology 1946;7:55–66.

9. Graef V., Baggenstoss A.H., Sauer W.G.,Spittel J.A. Jr. Venous thrombosis in non-specific ulcerative colitis. A necropsy study. Arch Intern Med. 1965;117:377–82. Doi: 10.1001/archi nte.1966.03870090061010.

10. Johns D.R. Cerebrovascular complications of inflammatory bowel disease. Am J Gastroenterol. 1991;86:367–70.

11. Katsanos A.H., Kosmidou M., Giannopoulos S., et al. Cerebral arterial infarction in inflammatory bowel diseases. Eur J Intern Med. 2014;25:37–44. Doi: 10.1016/j.ejim.2013.08.702.

12. Prior A., Strang F.A., Whorwell P.J. Internal carotid artery occlusion in association with Crohn’s disease. Dig Dis Sci. 1987;32:1047–50. Doi: 10.1007/BF01297197.

13. Landman C., Nahon S., Cosnes J., et al. Portomesenteric vein thrombosis in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:582–89.

14. Maccini D.M., Berg J.C., Bell G.A. Budd-Chiari syndrome and Crohn‘s disease. An unreported association. Dig Dis Sci. 1989;34:1933–36. Doi: 10.1007/BF01536715.

15. Stapleton S.R., Curley R.K., Simpson W.A. Cutaneous gangrene secondary to focal thrombosis–an important cutaneous manifestation of ulcerative colitis. Clin Exp Dermatol. 1989;14:387–89. Doi: 10.1111/j.1365-2230.1989. tb02594.x.

16. Schneiderman J.H., Sharpe J.A., Sutton D.M. Cerebral and retinal vascular complications of inflammatory bowel disease. Ann Neurol. 1979;5:331–37. Doi: 10.1002/ana.410050405.

17. Keyser B.J., Hass A.N. Retinal vascular disease in ulcerative colitis. Am J Ophthalmol. 1994;118:395–96.

18. Vayalambrone D., Ivanova T., Misra A. Nonischemic central retinal vein occlusion in an adolescent patient with ulcerative colitis. Case Rep Ophthalmol Med. 2011;2011:963583. Doi: 10.1155/2011/963583.

19. Mutlu B., Ermeydan C.M., Enç F., et al. Acute myocardial infarction in a young woman with severe ulcerative colitis. Int J Cardiol. 2002;83:183–85. Doi: 10.1016/S0167-5273(02)00043-8.

20. Murthy S.K., Nguyen G.C. Venous thromboembolism in inflammatory bowel disease: an epidemiological review. Am J Gastroenterol. 2011;106:713–18. Doi: 10.1038/ ajg.2011.53.

21. Bernstein C.N., Blanchard J.F., Houston D.S., Wajda A. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb Haemost. 2001;85:430–34.

22. Miehsler W., Reinisch W., Valic E., et al. Is inflammatory bowel disease an independent and disease specifi risk factor for thromboembolism? Gut. 2004;53:542–48. Doi: 10.1136/gut.2003.025411].

23. Huerta C., Johansson S., Wallander M.A., García Rodríguez L.A. Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Arch Intern Med. 2007;167:935–43. Doi: 10.1001/archinte.167.9.935.

24. Kappelman M.D., Horvath-Puho E., Sandler R.S., et al. Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study. Gut. 2011;60:937–43. Doi: 10.1136/gut.2010.228585.

25. Grainge M.J., West J., Card T.R. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet. 2010;375:657–63. Doi: 10.1016/S0140-6736(09)61963-2.

26. Bernstein C.N., Nabalamba A. Hospitalization-based major comorbidity of inflammatory bowel disease in Canada. Can J Gastroenterol. 2007;21:507–11.

27. Nguyen G.C., Sam J. Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. Am J Gastroenterol. 2008;103:2272–80. Doi: 10.1111/j.1572-0241.2008.02052.x.

28. Saleh T., Matta F., Yaekoub A.Y., et al. Risk of venous thromboembolism with inflammatory bowel disease. Clin Appl Thromb Hemost. 2011;17:254–58. Doi: 10.1177/1076029609360528.

29. Rothberg M.B., Lindenauer P.K., Lahti M., et al. Risk factor model to predict venous thromboembolism in hospitalized medical patients. J Hosp Med. 2011;6:202–9. Doi: 10.1002/jhm.888.

30. Sridhar A.R., Parasa S., Navaneethan U., et al. Comprehensive study of cardiovascular morbidity in hospitalized inflammatory bowel disease patients. J Crohns Colitis. 2011;5:287–94. Doi: 10.1016/j.crohns.2011.01.011.

31. Nguyen G.C., Boudreau H., Harris M.L., Maxwell C.V.Outcomes of obstetric hospitalizations among women with inflammatory bowel disease in the United States. Clin Gastroenterol Hepatol. 2009;7:329–34. Doi: 10.1016/j.cgh.2008.10.022.

32. Bröms G., Granath F., Linder M., et al. Complications from inflammatory bowel disease during pregnancy and delivery. Clin Gastroenterol Hepatol. 2012;10:1246–52. Doi: 10.1016/j.cgh.2012.08.018.

33. Merrill A., Millham F. Increased risk of postoperative deep vein thrombosis and pulmonary embolism in patients with inflammatory bowel disease: a study of National Surgical Quality Improvement Program patients. Arch Surg. 2012;147:120–24. Doi: 10.1001/archsurg.2011.297.

34. Wallaert J.B., De Martino R.R., Marsicovetere P.S., et al. Venous thromboembolism after surgery for inflammatory bowel disease: are there modifiable risk factors? Data from ACS NSQIP. Dis Colon Rectum. 2012;55:1138–44. Doi: 10.1097/ DCR.0b013e3182698f60.

35. Nylund C.M., Goudie A., Garza J.M., et al. Venous thrombotic events in hospitalized children and adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2013;56:485–91.

36. Yuhara H., Steinmaus C., Corley D., et al. Meta-analysis: the risk of venous thromboembolism in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013;37:953–62.

37. Papay P., Miehsler W., Tilg H., et al. Clinical presentation of venous thromboembolism in inflammatory bowel disease. J Crohns Colitis. 2013;7:723–29. Doi: 10.1016/j.crohns.2012.10.008.

38. Grip O., Svensson P.J., Lindgren S. Inflammatory bowel disease promotes venous thrombosis earlier in life. Scand J Gastroenterol. 2000;35:619–23. Doi: 10.1080/003655200750 023589.

39. Jackson L.M., O’Gorman P.J., O’Connell J., et al. Thrombosis in inflammatory bowel disease: clinical setting, procoagulant profile and factor V Leiden. QJM. 1997;90:183–88. Doi: 10.1093/ qjmed/90.3.183.

40. Solem C.A., Loftus E.V., Tremaine W.J., Sandborn W.J.Venous thromboembolism in inflammatory bowel disease. Am J Gastroenterol. 2004;99:97–101. Doi: 10.1046/ j.1572-0241.2003.04026.x.

41. Jess T., Gamborg M., Munkholm P., Sørensen T.I. Overall and cause-specifi mortality in ulcerative colitis: meta-analysis of population-based inception cohort studies. Am J Gastroenterol. 2007;102:609–17. Doi: 10.1111/j.1572-0241.2006.01000.x.

42. Duricova D., Pedersen N., Elkjaer M., et al. Overall and cause-specific mortality in Crohn’s disease: a meta-analysis of population-based studies. Inflamm Bowel Dis. 2010;16:347–53.

43. O’Connor O.J., Cahill R.A., Kirwan W.O., Redmond H.P. The incidence of postoperative venous thrombosis among patients with ulcerative colitis. Ir J Med Sci. 2005;174:20–2. Doi: 10.1007/BF03169142.

44. Danese S., Papa A., Saibeni S., et al. Inflammation and coagulation in inflammatory bowel disease: The clot thickens. Am J Gastroenterol. 2007;102:174–86. Doi: 10.1111/j.1572-0241.2006.00943.x.

45. Nogami H., Iiai T., Maruyama S., et al. Common carotid arterial thrombosis associated with ulcerative colitis. World J Gastroenterol. 2007;13:1755–57.

46. Richard S., Mione G., Perrin J., et al. Internal carotid thrombus in patients with inflammatory bowel disease: two cases. World J Gastroenterol. 2013;19:773–75. Doi: 10.3748/wjg.v19.i5.773.

47. Irving P.M., Alstead E.M., Greaves R.R., et al. Acute mesenteric infarction: an important cause of abdominal pain in ulcerative colitis. Eur J Gastroenterol Hepatol. 2005;17:1429–32. Doi: 10.1097/00042737-200512000-00027.

48. Szychta P., Reix T., Sevestre M.A., et al. Aortic thrombosis and ulcerative colitis. Ann Vasc Surg. 2001;15:402–4. Doi: 10.1007/s100160010068.

49. Novacek G., Haumer M., Schima W., et al. Aortic mural thrombi in patients with inflammatory bowel disease: report of two cases and review of the literature. Inflamm Bowel Dis. 2004;10:430–35. Doi: 10.1097/00054725-200407000-00016.

50. Levy P.J., Tabares A.H., Olin J.W. Lower extremity arterial occlusions in young patients with Crohn’s colitis and premature atherosclerosis: report of six cases. Am J Gastroenterol. 1997;92:494–97.

51. Haumer M., Teml A., Dirisamer A., et al. Severe ulcerative colitis complicated by an arterial thrombus in the brachiocephalic trunk. Inflamm Bowel Dis. 2007;13:937–38. Doi: 10.1002/ibd.20116].

52. Di Fabio F., Obrand D., Satin R., Gordon P.H. Intra-abdominal venous and arterial thromboembolism in inflammatory bowel disease. Dis Colon Rectum. 2009;52:336–42. Doi: 10.1007/DCR.0b013e31819a235d.

53. Ha C., Magowan S., Accortt N.A., et al. Risk of arterial thrombotic events in inflammatory bowel disease. Am J Gastroenterol. 2009;104:1445–51. Doi: 10.1038/ajg.2009.81.

54. Kristensen S.L., Ahlehoff O., Lindhardsen J., et al. Disease activity in inflammatory bowel disease is associated with increased risk of myocardial infarction, stroke and cardiovascular death – a Danish nationwide cohort study. PLoS One. 2013;8:e56944. Doi: 10.1371/journal.pone.0056944eb.

55. Andersohn F., Waring M., Garbe E. Risk of ischemic stroke in patients with Crohn’s disease: a population-based nested case-control study. Inflamm Bowel Dis. 2010;16:1387–92. Doi: 10.1002/ibd.21187.

56. Bernstein C.N., Wajda A., Blanchard J.F. The incidence of arterial thromboembolic diseases in inflammatory bowel disease: a population-based study. Clin Gastroenterol Hepatol. 2008;6:41–5. Doi: 10.1016/j.cgh.2007.09.016.

57. Yarur A.J., Deshpande A.R., Pechman D.M., et al. Inflammatory bowel disease is associated with an increased incidence of cardiovascular events. Am J Gastroenterol. 2011;106:741–47. Doi: 10.1038/ajg.2011.63.

58. Rungoe C., Basit S., Ranthe M.F., et al. Risk of ischaemic heart disease in patients with inflammatory bowel disease: a nationwide Danish cohort study. Gut. 2013;62:689–94. Doi: 10.1136/ gutjnl-2012-303285.

59. Zöller B., Li X., Sundquist J., Sundquist K. Risk of subsequent ischemic and hemorrhagic stroke in patients hospitalized for immune-mediated diseases: a nationwide follow-up study from Sweden. BMC Neurol. 2012;12:41. Doi: 10.1186/1471-2377-12-41.

60. Singh S., Singh H., Loftus E.V., Pardi D.S. Risk of cerebrovascular accidents and ischemic heart disease in patients with inflammatory bowel disease: a systematic review and metaanalysis. Clin Gastroenterol Hepatol. 2014;12:382–93. Doi: 10.1016/j.cgh.2013.08.023.

61. Dorn S.D., Sandler R.S. Inflammatory bowel disease is not a risk factor for cardiovascular disease mortality: results from a systematic review and meta-analysis. Am J Gastroenterol. 2007;102:662–67. Doi: 10.1111/ j.1572-0241.2006.01018.x.

62. Osterman M.T., Yang Y.X., Brensinger C., et al. No increased risk of myocardial infarction among patients with ulcerative colitis or Crohn‘s disease. Clin Gastroenterol Hepatol. 2011;9:875–80. Doi: 10.1016/j.cgh.2011.06.032.

63. Geerts W.H., Bergqvist D., Pineo G.F., et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133:381S–453S. Doi: 10.1378/chest.08-0656.

64. Kornbluth A., Sachar D.B. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105:501–23; quiz 524. Doi: 10.1038/ajg.2009.727.

65. Mowat C., Cole A., Windsor A., et al. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011;60:571–607. Doi: 10.1136/gut.2010.224154.

66. Bitton A., Buie D., Enns R., et al. Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statements. Am J Gastroenterol. 2012;107:179–94. Doi: 10.1038/ajg.2011.386.

67. Van Assche G., Dignass A., Bokemeyer B., et al. Second European evidencebased consensus on the diagnosis and management of ulcerative colitis part 3: special situations. J Crohns Colitis. 2013;7:1–33. Doi: 10.1016/j.crohns.2012.09.005.

68. Harbord M., Annese V., Vavricka S.R., et al.; The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. J Crohn’s Colitis. 2016;10(3):239–54. Doi:10.1093/ecco-jcc/jjv213.

69. Folwaczny C., Wiebecke B., Loeschke K. Unfractioned heparin in the therapy of patients with highly active inflammatory bowel disease. Am J Gastroenterol. 1999;94:1551–55.

70. Ang Y.S., Mahmud N., White B., et al. Randomized comparison of unfractionated heparin with corticosteroids in severe active inflammatory bowel disease. Aliment Pharmacol Ther. 2000;14:1015–22.

71. Bloom S., Kiilerich S., Lassen M.R., et al. Low molecular weight heparin (tinzaparin) vs. placebo in the treatment of mild to moderately active ulcerative colitis. Aliment Pharmacol Ther. 2004;19:871–78.

72. Pastorelli L., Saibeni S., Spina L., et al. Oral, colonic-release low-molecularweight heparin: an initial open study of Parnaparin-MMX for the treatment of mild-to-moderate left-sided ulcerative colitis. Aliment Pharmacol Ther. 2008;28:581–88. Doi: 10.1111/j.1365-2036.2008.03757.x.

73. Shen J., Ran Z.H., Tong J.L., Xiao S.D. Meta-analysis: The utility and safety of heparin in the treatment of active ulcerative colitis. Aliment Pharmacol Ther. 2007;26:653–63.

74. Ra G., Thanabalan R., Ratneswaran S., Nguyen G.C. Predictors and safety of venous thromboembolism prophylaxis among hospitalized inflammatory bowel disease patients. J Crohns Colitis. 2013;7:e479-e485. Doi:10.1016/j.crohns.2013.03.002.

75. Nguyen G.C., Wu H., Gulamhusein A., et al. The utility of screening for asymptomatic lower extremity deep venous thrombosis during inflammatory bowel disease flares: a pilot study. Inflamm Bowel Dis. 2013;19:1053–58. Doi: 10.1097/MIB.0b013e3182802a65.

76. Bryant R.V., Jairath V., Curry N., Travis S.P. Thrombosis in inflammatory bowel disease: are we tailoring prophylaxis to those most at risk? J Crohns Colitis. 2014;8:166–71. Doi: 10.1016/j.crohns.2013.09.007.

77. Nguyen G.C. IBD: postoperative VTE prophylaxis in IBD. Nat Rev Gastroenterol Hepatol. 2013;10:5–6. Doi: 10.1038/nrgastro.2012.233.

78. Scarpa M., Pilon F., Pengo V., et al. Deep venous thrombosis after surgery for inflammatory bowel disease: is standard dose low molecular weight heparin prophylaxis enough? World J Surg 2010;34:1629–36. Doi: 10.1007/s00268-010-0490-8.

79. Nguyen G.C., Yeo E.L. Prophylaxis of venous thromboembolism in IBD. Lancet. 2010;375:616–17. Doi: 10.1016/S0140-6736(10)60174-2.

80. Zitomersky N.L., Verhave M., Trenor C.C. Thrombosis and inflammatory bowel disease: a call for improved awareness and prevention. Inflamm Bowel Dis. 2011;17:458–70. Doi: 10.1002/ibd.21334.

81. Tabibian J.H., Streiff M.B. Inflammatory bowel disease-associated thromboembolism: a systematic review of outcomes with anticoagulation versus catheter-directed thrombolysis. Inflamm Bowel Dis. 2012;18:161–71. Doi: 10.1002/ibd.21307.

82. Nguyen G.C., Bernstein C.N. Duration of anticoagulation for the management of venous thromboembolism in inflammatory bowel disease: a decision analysis. Am J Gastroenterol. 2013;108:1486–95. Doi: 10.1038/ajg.2013.220.

83. van der Hulle T., Kooiman J., den Exter P.L., et al. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost. 2014;12:320–28. Doi: 10.1111/jth.12485.

84. Razik R., Bernstein C.N., Sam J., et al. Survey of perceptions and practices among Canadian gastroenterologists regarding the prevention of venous thromboembolism for hospitalized inflammatory bowel disease patients. Can J Gastroenterol. 2012;26:795–98.

85. Sam J.J., Bernstein C.N., Razik R., et al. Physicians’ perceptions of risks and practices in venous thromboembolism prophylaxis in inflammatory bowel disease. Dig Dis Sci. 2013;58:46–52. Doi: 10.1007/ s10620-012-2435-6.

86. Tinsley A., Naymagon S., Enomoto L.M., et al. Rates of pharmacologic venous thromboembolism prophylaxis in hospitalized patients with active ulcerative colitis: results from a tertiary care center. J Crohns Colitis. 2013;7:e635–e640. Doi: 10.1016/ j.crohns.2013.05.002.

87. Allen J.I. Mind the gap: venous thromboembolism prophylaxis in patients hospitalized with inflammatory bowel disease. Dig Dis Sci. 2013;58:1–4. Doi: 10.1007/s10620-012-2492-x.

88. Nguyen G.C., Bernstein C.N., Bitton A., et al. Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology. Gastroenterology. 2014;146:835–48. Doi: 10.1053/j.gastro.2014.01.042.


Об авторах / Для корреспонденции


Автор для связи: А.А. Лищинская, к.м.н., старший науч. сотр. отделения воспалительных заболеваний кишечника, Московский клинический научно-практический центр им. А.С. Логинова ДЗ Москвы, Москва, Россия; e-mail: lalbina@inbox.ru
Адрес: 111123, Россия, Москва, шоссе Энтузиастов, 86


Бионика Медиа